Herzliya-based venture capital firm launches second fund to back locally founded startups in areas of digital health, medical devices, diagnostics, and life sciences
Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics
March 01, 2021 16:00 ET | Source: Artizan Biosciences, Inc. Artizan Biosciences, Inc. New Haven, Connecticut, UNITED STATES
Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease
Series A-2 led by Hatteras Venture Partners and Biohaven
Donnie McGrath, M.D., and Seth Rudnick, M.D., join Artizan’s
board of directors
NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) Artizan Biosciences, Inc. (“Artizan”), a biotechnology company focused on addressing inflammatory diseases involving the human intestinal microbiota, today announced the company has raised $11 million in a Series A-2 financing led by existing investor Hatteras Venture Partners and new investor Biohaven Therapeutics Ltd. (“Biohaven”). Additional new i
Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Liquidia Corporation Announces Chief Executive Officer Transition
Liquidia Corporation Announces Chief Executive Officer Transition
RESEARCH TRIANGLE PARK, N.C., Dec. 14, 2020 Liquidia Corporation (NASDAQ: LQDA) today announced Damian deGoa has been appointed as Chief Executive Officer (CEO) and a director of the Company, effective immediately. He succeeds Neal F. Fowler who has retired as CEO and a director of the Company. Mr. Fowler has agreed to provide assistance to the Company for a short period of time to support a smooth transition.
“Damian is a strategic and proven leader in the healthcare industry, having led several companies in various stages of operations, most notably as Chief Executive Officer of RareGen from its formation in Summer 2018 through its acquisition by Liquidia in November 2020,” said Dr. Stephen Bloch, Chairman of the Company’s Board of Directors. “We are thrilled to welcome Damian’s wealth of experience in the pulmonary arterial hypertensio